OBJECTIVE: To evaluate in vitro the potential links between sialyl Lewis X (sLeX) and cancer stem cells (CSC) in head and neck squamous cell carcinoma (HNSCC). HNSCC is an aggressive malignancy with high mortality mainly due to metastasis. CSC have emerged as important players in HNSCC metastasis. sLeX is a tetrasaccharide carbohydrate known to play a key role in metastatic dissemination by promoting binding of the tumor cells to the endothelium. STUDY DESIGN: Experimental, in vitro. SETTING: Laboratory of Head and Neck Cancer Metastasis, University of Michigan. SUBJECTS AND METHODS: A panel of stage- and anatomic-site specific primary and metastatic HNSCC cell lines was assessed by flow cytometry to quantify sLeX relative expression levels. Serum-free conditioned media from the same HNSCC lines was collected over a time course of 72 hours and assessed by Western blot for secreted sLeX expression. Representative HNSCC cell lines were cultured as floating orospheres (condition that enhance CSC growth) or under normal adherent conditions and characterized by flow cytometry for CSC markers (CD44, aldehyde dehydrogenase [ALDH]) comparatively with sLeX expression. RESULTS: sLeX is predominantly expressed in carcinomas originating from the oral cavity. Secreted sLeX is also found to be high in oral carcinomas and increased over the analyzed time course. Floating orospheres were strongly positive for CD44 and ALDH, confirming CSC enrichment of the orospheres. Tumor cells grown as orospheres are 95% to 100% positive for sLeX compared to 10% to 40% of adherent counterpart. CONCLUSION: These studies provide the first evidence of sLeX relationship with CSC in HNSCC.
OBJECTIVE: To evaluate in vitro the potential links between sialyl Lewis X (sLeX) and cancer stem cells (CSC) in head and neck squamous cell carcinoma (HNSCC). HNSCC is an aggressive malignancy with high mortality mainly due to metastasis. CSC have emerged as important players in HNSCC metastasis. sLeX is a tetrasaccharide carbohydrate known to play a key role in metastatic dissemination by promoting binding of the tumor cells to the endothelium. STUDY DESIGN: Experimental, in vitro. SETTING: Laboratory of Head and Neck Cancer Metastasis, University of Michigan. SUBJECTS AND METHODS: A panel of stage- and anatomic-site specific primary and metastatic HNSCC cell lines was assessed by flow cytometry to quantify sLeX relative expression levels. Serum-free conditioned media from the same HNSCC lines was collected over a time course of 72 hours and assessed by Western blot for secreted sLeX expression. Representative HNSCC cell lines were cultured as floating orospheres (condition that enhance CSC growth) or under normal adherent conditions and characterized by flow cytometry for CSC markers (CD44, aldehyde dehydrogenase [ALDH]) comparatively with sLeX expression. RESULTS: sLeX is predominantly expressed in carcinomas originating from the oral cavity. Secreted sLeX is also found to be high in oral carcinomas and increased over the analyzed time course. Floating orospheres were strongly positive for CD44 and ALDH, confirming CSC enrichment of the orospheres. Tumor cells grown as orospheres are 95% to 100% positive for sLeX compared to 10% to 40% of adherent counterpart. CONCLUSION: These studies provide the first evidence of sLeX relationship with CSC in HNSCC.
Entities:
Keywords:
CD44; head and neck squamous cell carcinomas; in vitro analysis; sLeX (sialyl Lewis X); stem cells
Authors: Sudha Krishnamurthy; Zhihong Dong; Dmitry Vodopyanov; Atsushi Imai; Joseph I Helman; Mark E Prince; Max S Wicha; Jacques E Nör Journal: Cancer Res Date: 2010-11-23 Impact factor: 12.701
Authors: M E Prince; R Sivanandan; A Kaczorowski; G T Wolf; M J Kaplan; P Dalerba; I L Weissman; M F Clarke; L E Ailles Journal: Proc Natl Acad Sci U S A Date: 2007-01-08 Impact factor: 11.205
Authors: Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone Journal: Cancer Res Date: 2007-02-01 Impact factor: 12.701
Authors: Matthew R Clay; Mark Tabor; John Henry Owen; Thomas E Carey; Carol R Bradford; Gregory T Wolf; Max S Wicha; Mark E Prince Journal: Head Neck Date: 2010-09 Impact factor: 3.147
Authors: Piero Dalerba; Scott J Dylla; In-Kyung Park; Rui Liu; Xinhao Wang; Robert W Cho; Timothy Hoey; Austin Gurney; Emina H Huang; Diane M Simeone; Andrew A Shelton; Giorgio Parmiani; Chiara Castelli; Michael F Clarke Journal: Proc Natl Acad Sci U S A Date: 2007-06-04 Impact factor: 11.205
Authors: Josiah Ochieng; Gladys N Nangami; Olugbemiga Ogunkua; Isabelle R Miousse; Igor Koturbash; Valerie Odero-Marah; Lisa J McCawley; Pratima Nangia-Makker; Nuzhat Ahmed; Yunus Luqmani; Zhenbang Chen; Silvana Papagerakis; Gregory T Wolf; Chenfang Dong; Binhua P Zhou; Dustin G Brown; Anna Maria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Rabeah Al-Temaimi; Fahd Al-Mulla; William H Bisson; Sakina E Eltom Journal: Carcinogenesis Date: 2015-06 Impact factor: 4.944
Authors: Silvana Papagerakis; Emily Bellile; Lisa A Peterson; Maria Pliakas; Katherine Balaskas; Sara Selman; David Hanauer; Jeremy M G Taylor; Sonia Duffy; Gregory Wolf Journal: Cancer Prev Res (Phila) Date: 2014-12
Authors: M Matossian; C Vangelderen; P Papagerakis; L Zheng; G T Wolf; S Papagerakis Journal: Int J Immunopathol Pharmacol Date: 2014 Oct-Dec Impact factor: 3.219
Authors: Silvana Papagerakis; Giuseppe Pannone; Li Zheng; Imad About; Nawar Taqi; Nghia P T Nguyen; Margarite Matossian; Blake McAlpin; Angela Santoro; Jonathan McHugh; Mark E Prince; Petros Papagerakis Journal: Exp Cell Res Date: 2014-05-05 Impact factor: 3.905
Authors: Vincenzo Desiderio; Petros Papagerakis; Virginia Tirino; Li Zheng; Margarite Matossian; Mark E Prince; Francesca Paino; Luigi Mele; Federica Papaccio; Roberta Montella; Gianpaolo Papaccio; Silvana Papagerakis Journal: Oncotarget Date: 2015-01-01